Identification of Resistance Mechanisms to Evaluate Therapeutic Options for Refractory Yolk-Sac Tumors Using Multikinase Inhibitors or Antibody (CLDN6)-/ Nanobody (Cxcr4)-Drug-conjugates

M. A. Skowron,F. Bremmer,M. Kotthoff, K. Ruhnke, G. A. Wakileh, P. Bierholz, A. Stephan, F. Parmaksiz,Y. Che, S. Pauls, A. Stefanski, S. Anbuhl, R. Heukers, M. J. Smit,K. Stuehler,P. Albers,D. Nettersheim

EUROPEAN UROLOGY（2023）

Cited 0|Views23

Key words

Novel Therapies

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined